Brought to you by 
Glycotope raises €55mm through Series C round
28 Mar 2014
Executive Summary
Glycotope GMBH (protein glycosylation) raised €55mm ($76.5mm) through its Series C round. Existing investors Jossa Arznei GMBH and ELSA GMBH (Eckert Life Science Accelerator) provided the funding, which will be used for Phase IIb trials in the US and Europe of the company’s PankoMab-GEX for ovarian cancer (also in Phase I for non-small cell lung cancer) and CetuGEX for multiple solid tumor types. Glycotope states it has now raised over €130mm in venture funding, including a €40mm Series A round in 2007 and a €36mm Series B in 2011.
Deal Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Pharmaceuticals
- Nutraceuticals
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Glycotope raises €55mm through Series C round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice